Acumen Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported a net loss of $28.8 million for the first quarter of 2025, compared to a net loss of $14.9 million in the same period of 2024. The company holds cash, cash equivalents, and marketable securities totaling $197.9 million as of March 31, 2025, which is expected to support its clinical and operational activities into early 2027. In significant business developments, Acumen has fully enrolled its ALTITUDE-AD Phase 2 study, which investigates the efficacy, safety, and tolerability of sabirnetug for treating early Alzheimer's disease. The study includes 542 participants, and the company anticipates reporting topline results in late 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。